Abstract
Globally, lung cancer has risen to the leading cause of cancer mortality in both sexes. Currently, the only potentially curable stage of the disease is the pulmonary nodule. Since numerous studies have documented that in any population of nodules only approximately fifty percent ultimately prove to be neoplastic, non-invasive evaluation of nodules to reduce surgical morbidity, mortality and cost is desirable. Recent nuclear medicine imaging modalities have shown promise in the accurate non-invasive characterization of pulmonary nodules. These new technologies exploit the biomolecular alterations of neoplastic cells. The somatostatin receptor is relatively over-expressed in pulmonary neoplastic tissue when compared to most benign tissue processes. A somatostatin analog-technetium ligand (99mTc depreotide) has shown significant promise in the rapid, convenient, accurate and cost effective characterization of lung nodules with conventional gamma camera systems. The development of this agent required synthesis of a somatostatin receptor ligand of high affinity for the receptor subtypes operative in pulmonary neoplasia and the incorporation of technetium without loss of pharmacore specificity.
Keywords: lung cancer, pulmonary nodule, pulmonary neoplastic tissue, historical perspectives, fdg-pet, gtp-binding-protein-coupled, human depreotide, neoplasms
Current Pharmaceutical Design
Title: Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Volume: 8 Issue: 20
Author(s): Jay Blum, Hirsch Handmaker and Neal A. Rinne
Affiliation:
Keywords: lung cancer, pulmonary nodule, pulmonary neoplastic tissue, historical perspectives, fdg-pet, gtp-binding-protein-coupled, human depreotide, neoplasms
Abstract: Globally, lung cancer has risen to the leading cause of cancer mortality in both sexes. Currently, the only potentially curable stage of the disease is the pulmonary nodule. Since numerous studies have documented that in any population of nodules only approximately fifty percent ultimately prove to be neoplastic, non-invasive evaluation of nodules to reduce surgical morbidity, mortality and cost is desirable. Recent nuclear medicine imaging modalities have shown promise in the accurate non-invasive characterization of pulmonary nodules. These new technologies exploit the biomolecular alterations of neoplastic cells. The somatostatin receptor is relatively over-expressed in pulmonary neoplastic tissue when compared to most benign tissue processes. A somatostatin analog-technetium ligand (99mTc depreotide) has shown significant promise in the rapid, convenient, accurate and cost effective characterization of lung nodules with conventional gamma camera systems. The development of this agent required synthesis of a somatostatin receptor ligand of high affinity for the receptor subtypes operative in pulmonary neoplasia and the incorporation of technetium without loss of pharmacore specificity.
Export Options
About this article
Cite this article as:
Blum Jay, Handmaker Hirsch and Rinne A. Neal, Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393828
DOI https://dx.doi.org/10.2174/1381612023393828 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Patent Review of Novel Nanostructrued Devices, Nanofabrication Methods and Applications in Nanofluidics and Nanomedicine
Recent Patents on Nanotechnology LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics A Guide to Treatment of Sarcoidosis
Current Drug Therapy MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine
Current Pharmaceutical Design Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
Recent Patents on DNA & Gene Sequences MicroRNAs as Cancer Biomarkers
MicroRNA Agents Targeting Prostate Cancer Bone Metastasis
Anti-Cancer Agents in Medicinal Chemistry Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets Self-Renewal Versus Differentiation in Hematopoietic Stem and Progenitor Cells: A Focus on Asymmetric Cell Divisions
Current Stem Cell Research & Therapy Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery